Share

September 16, 2014; 83 (12) Article

Course of psychiatric symptoms and global cognition in early Parkinson disease

Patricia de la Riva, Kara Smith, Sharon X. Xie, Daniel Weintraub
First published August 15, 2014, DOI: https://doi.org/10.1212/WNL.0000000000000801
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1022

Share

Article Information

vol. 83 no. 12 1096-1103
DOI: 
https://doi.org/10.1212/WNL.0000000000000801
PubMed: 
25128183
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received March 23, 2014
  • Accepted in final form June 23, 2014
  • First Published August 15, 2014.

Article Versions

Copyright & Usage: 
© 2014 American Academy of Neurology

Author Disclosures

    1. Patricia de la Riva, MD,
    2. Kara Smith, MD,
    3. Sharon X. Xie, PhD and
    4. Daniel Weintraub, MD
  1. Patricia de la Riva, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1)Group of Young Neurologists of the Spanish Society of Neurology

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Kara Smith, MD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. I receive an educational grant from Medtronic as a partial source of funding for my fellowship.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Sharon X. Xie, PhD and
    4. Scientific Advisory Boards:

    1. Dr. Xie served as a consultant to Roche on a clinical trial unrelated to this study.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Alzheimer's & Dementia, Associate Editor, 2013-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Dr. Xie received funding from MJ Fox foundation and NIH grant R21-AT005230. Dr. Xie is currently funded by NIH grants P30-AG010124, P50-NS053488,P01-AG032953, P01-AG017586, R01-AT005074, R01-AG040271, and U01-NS082134.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Daniel Weintraub, MD
    5. Scientific Advisory Boards:

    1. Commercial - Pfizer, Teva Pharmaceuticals, Avanir Pharmaceuticals, Merck & Co., Lundbeck Inc., UCB, Bristol- Myers Squib Company, Novartis, Clintrex, Theravance, Medivation Non-profit - CHDI, ADCS

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Serves on Editorial Board of Movement Disorders Journal and Journal of Parkinson's Disease

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. Licensing fees from the University of Pennsylvania for the QUIP and QUIP-RS

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Novartis Pharmaceuticals, PI, 2011-

    Research Support, Government Entities:

    1. NINDS, P50 NS053488, Investigator, 2007- NINDS, R01NS065087, Investigator, 2009-2012 NIA, RO1AG031348, Investigator, 2008- NIA, U19 AG10483-22, DSMB Chair, 2013-

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Michael J. Fox Foundation for Parkinson's Research, PI, 2009-2011 Michael J. Fox Foundation for Parkinson's Research, PI, 2011- Michael J. Fox Foundation for Parkinson's Research, Investigator, 2011-

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. Licensing fees from the University of Pennsylvania for licensing of Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease.

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. Expert testimony for defense in 2012-2014 in two lawsuits related to impulse control disorders in Parkinson's disease

  1. From the Department of Neurology (P.d.l.R.), University Hospital Donostia, San Sebastián, Spain; Department of Biostatistics and Epidemiology (S.X.X.) and Departments of Neurology and Psychiatry (D.W.), Perelman School of Medicine at the University of Pennsylvania (K.S.), Philadelphia; and Department of Veterans Affairs (D.W.), Philadelphia VA Medical Center.
  1. Correspondence to Dr. de la Riva: patricia.delariva{at}gmail.com

Article usage

Article usage: August 2014 to November 2023

AbstractFullPdfSource
Aug 20141742087Highwire
Sep 2014212936122Highwire
Oct 2014526216161Highwire
Nov 20142021410Highwire
Dec 20141332018Highwire
Jan 2015169179Highwire
Feb 201514966Highwire
Mar 2015120810Highwire
Apr 20158733Highwire
May 2015117175Highwire
Jun 20157683Highwire
Jul 201584118Highwire
Aug 20156744Highwire
Sep 20159936Highwire
Sep 201502111pmc
Oct 20158476Highwire
Oct 201504325pmc
Nov 20155812Highwire
Nov 201502918pmc
Dec 20158072Highwire
Dec 201502621pmc
Jan 20167932Highwire
Jan 201602421pmc
Feb 20164044Highwire
Feb 201602315pmc
Mar 20162433Highwire
Mar 201601917pmc
Apr 20163211Highwire
Apr 201603633pmc
May 20166120Highwire
May 201603215pmc
Jun 20162810Highwire
Jun 201603218pmc
Jul 20162812Highwire
Jul 20160169pmc
Aug 20162911Highwire
Aug 201601715pmc
Sep 20162911Highwire
Sep 201602618pmc
Oct 20163801Highwire
Oct 201602413pmc
Nov 20162402Highwire
Nov 20160167pmc
Dec 20162044Highwire
Dec 20160155pmc
Jan 20173213Highwire
Jan 201702519pmc
Feb 20174321Highwire
Feb 201702015pmc
Mar 20173001Highwire
Mar 201702314pmc
Apr 20173611Highwire
Apr 2017101413pmc
May 20173600Highwire
May 201762318pmc
Jun 20171410Highwire
Jun 201761617pmc
Jul 20171521Highwire
Jul 2017101414pmc
Aug 20172101Highwire
Aug 2017599pmc
Sep 20171922Highwire
Sep 201771313pmc
Oct 20172400Highwire
Oct 2017111718pmc
Nov 20172231Highwire
Nov 201751719pmc
Dec 20172421Highwire
Jan 20181911Highwire
Feb 20182330Highwire
Mar 20186053Highwire
Apr 20184673Highwire
Apr 201881213pmc
May 20185510Highwire
Jun 20183421Highwire
Jun 2018687pmc
Jul 20182822Highwire
Aug 20182622Highwire
Aug 2018152218pmc
Sep 20182201Highwire
Oct 20184701Highwire
Nov 20183011Highwire
Dec 20184800Highwire
Jan 20192600Highwire
Feb 20192200Highwire
Mar 20193112Highwire
Apr 20193711Highwire
May 20191311Highwire
Jun 20192112Highwire
Jul 20192011Highwire
Aug 20193210Highwire
Sep 20192221Highwire
Oct 20192501Highwire
Nov 20193000Highwire
Dec 20191502Highwire
Jan 20203600Highwire
Feb 20202610Highwire
Mar 20204832Highwire
Apr 20203200Highwire
May 20203000Highwire
Jun 20202700Highwire
Jul 20201900Highwire
Aug 20201911Highwire
Sep 20201020Highwire
Oct 20203600Highwire
Nov 20202433Highwire
Dec 20203301Highwire
Jan 20212210Highwire
Feb 20214121Highwire
Mar 20213920Highwire
Apr 20213410Highwire
May 20212110Highwire
Jun 20213611Highwire
Jul 20213211Highwire
Aug 20213721Highwire
Sep 20213300Highwire
Oct 20212411Highwire
Nov 20213300Highwire
Dec 20214600Highwire
Jan 20221900Highwire
Feb 20226511Highwire
Mar 20226710Highwire
Apr 20226840Highwire
May 20223321Highwire
Jun 20223722Highwire
Jul 20223501Highwire
Aug 20222221Highwire
Sep 20224600Highwire
Oct 20224410Highwire
Nov 20223110Highwire
Dec 20221832Highwire
Jan 20234522Highwire
Feb 20233122Highwire
Mar 20233400Highwire
Apr 20234200Highwire
May 20234934Highwire
Jun 20234132Highwire
Jul 20235200Highwire
Aug 20233930Highwire
Sep 20236411Highwire
Oct 202314410Highwire
Nov 202320112Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me

Recommended articles